Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

Core Insights - Precigen, Inc. announced participation in two virtual fireside chats to discuss the recent FDA approval of a therapy for recurrent respiratory papillomatosis [1][2] Group 1: Company Overview - Precigen is a biopharmaceutical company focused on innovative precision medicines aimed at treating difficult diseases with high unmet needs [3] - The company is committed to advancing scientific breakthroughs from proof-of-concept to commercialization [3] - Precigen is developing a diverse pipeline of therapies in immuno-oncology, autoimmune disorders, and infectious diseases [3] Group 2: Upcoming Events - The first virtual fireside chat will be hosted by Jennifer Kim from Cantor on August 27, 2025, featuring CEO Helen Sabzevari and CCO Phil Tennant [2] - The second chat will be moderated by Swayampakula Ramakanth from H.C. Wainwright on September 2, 2025, also featuring CEO Helen Sabzevari and CCO Phil Tennant [2] - Live webcasts of these events will be accessible through Precigen's website [2]